Celldex Therapeutics Inc

Compare

1,240 Followers

CLDX Stock Chart & Stats

$26.73

-$0.90(-3.26%)

At close: Jan 08 4:00 PM EST

$26.73

-$0.90(-3.26%)

Day’s Range― - ―

52-Week Range$14.40 - $29.05

Previous CloseN/A

Volume733.18K

Average Volume (3M)924.00K

Market Cap

$1.78B

Enterprise Value$729.97M

Total Cash (Recent Filing)$630.34M

Total Debt (Recent Filing)$3.03M

Price to Earnings (P/E)―

Beta1.47

Next Earnings

Nov 05, 2025

EPS Estimate

-0.9

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.85

Shares Outstanding66,406,550

10 Day Avg. Volume678,194

30 Day Avg. Volume924,000

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.41

Enterprise Value/Revenue126.05

Enterprise Value/Gross Profit146.82

Enterprise Value/Ebitda-3.15

Forecast

1Y Price Target

$49.20

Price Target Upside84.06% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessCelldex has two pivotal Phase III trials ongoing for barzolvolimab in chronic spontaneous urticaria, with a high likelihood of clinical success based on Phase II results.

Efficacy In Respiratory ConditionsThe data suggests that CDX-622 could be uniquely positioned for conditions where TSLP and mast cells may play a role, particularly in certain respiratory conditions.

Safety ProfileCDX-622 shows preferential inhibition of soluble SCF over membrane SCF, resulting in a differentiated safety profile compared to historical KIT inhibitors.

Bears Say

Toxicity RiskSome KIT-mediated toxicity risk remains, specifically regarding the rate/severity of neutropenia and how this profile impacts any potential monitoring requirements.

Celldex News

Celldex announces initial positive results from Phase 1 trial of CDX-622

Celldex (CLDX) announced positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that...

3d ago

CLDX

Celldex initiated with an Outperform at Mizuho

Mizuho initiated coverage of Celldex (CLDX) with an Outperform rating and $48 price target The firm sees barzolvolimab...

13d ago

CLDX

Celldex initiated with an Underweight at Barclays

Barclays initiated coverage of Celldex (CLDX) with an Underweight rating and $25 price target The firm launched coverage...

20d ago

CLDX

Celldex’s Promising Clinical Data and Strategic Development Plans Drive Buy Rating

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Celldex today and set a price target of...

2d ago

CLDX

Promising Developments in Celldex’s CDX-622 Drive Buy Rating

Analyst Judah Frommer from Morgan Stanley maintained a Buy rating on Celldex and keeping the price target at...

2d ago

CLDX

Celldex’s barzo shows strong efficacy in CSU patients, says H.C. Wainwright

Celldex (CLDX), at EADV 2025, disclosed new data from its Phase 2 study assessing barzolvolimab in CSU, showing...

2M ago

CLDX

Celldex’s Barzolvolimab Shows Promising Efficacy in Treating Chronic Spontaneous Urticaria Across Patient Subgroups

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Celldex and keeping the price target at...

2M ago

CLDX

Celldex announces new barzolvolimab data at EADV congress

Celldex (CLDX) announced new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E levels in patients...

2M ago

CLDX

Celldex Therapeutics Advances in Prurigo Nodularis Treatment with Barzolvolimab Study

Celldex Therapeutics (($CLDX)) announced an update on their ongoing clinical study. Study Overview: Celldex Therapeutics is conducting a...

2M ago

CLDX

Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria

Celldex Therapeutics (($CLDX)) announced an update on their ongoing clinical study. Study Overview: Celldex Therapeutics is conducting a...

2M ago

CLDX

Celldex Therapeutics Advances Phase 3 Trial for Chronic Spontaneous Urticaria Treatment

Celldex Therapeutics (($CLDX)) announced an update on their ongoing clinical study. Celldex Therapeutics is conducting a Phase 3...

2M ago

CLDX

3 Best Stocks to Buy Now, 8/25/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

2M ago

BHVN

CLDX

Celldex’s Barzolvolimab: Promising Safety Profile Supports Buy Rating Despite EoE Trial Setback

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on CLDX stock, giving a Buy rating on...

2M ago

CLDX

Celldex data supports positive Eupraxia thesis, says H.C. Wainwright

H.C. Wainwright believes Celldex’s (CLDX) Phase 2 data for barzolvolimab in patients with eosinophilic esophagitis supports the positive...

2M ago

CLDX

EPRX

CLDX FAQ

What was Celldex Therapeutics Inc’s price range in the past 12 months?

Celldex Therapeutics Inc lowest stock price was $14.40 and its highest was $29.05 in the past 12 months.

What is Celldex Therapeutics Inc’s market cap?

Celldex Therapeutics Inc’s market cap is $1.78B.

When is Celldex Therapeutics Inc’s upcoming earnings report date?

Celldex Therapeutics Inc’s upcoming earnings report date is Nov 05, 2025 which is in 3 days.

How were Celldex Therapeutics Inc’s earnings last quarter?

Celldex Therapeutics Inc released its earnings results on Aug 07, 2025. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$0.856 by $0.006.

Is Celldex Therapeutics Inc overvalued?

According to Wall Street analysts Celldex Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Celldex Therapeutics Inc pay dividends?

Celldex Therapeutics Inc does not currently pay dividends.

What is Celldex Therapeutics Inc’s EPS estimate?

Celldex Therapeutics Inc’s EPS estimate is -0.9.

How many shares outstanding does Celldex Therapeutics Inc have?

Celldex Therapeutics Inc has 66,406,550 shares outstanding.

What happened to Celldex Therapeutics Inc’s price movement after its last earnings report?

Celldex Therapeutics Inc reported an EPS of -$0.85 in its last earnings report, beating expectations of -$0.856. Following the earnings report the stock price went down -2.593%.

Which hedge fund is a major shareholder of Celldex Therapeutics Inc?

Currently, no hedge funds are holding shares in CLDX

Celldex Stock Smart Score

Neutral

Fundamentals

Return on Equity

-27.17%

Trailing 12-Months

Asset Growth

-18.12%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Celldex Therapeutics Inc

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative immunotherapy products for the treatment of various types of cancer and other serious diseases. The company operates primarily in the biotechnology sector, leveraging its proprietary technology platforms to create targeted therapies that harness the body's immune system to fight tumors. Celldex's core products include monoclonal antibodies and other biologics designed to improve patient outcomes through precision medicine.

Celldex (CLDX) Earnings & Revenues

Historic Earnings Reports

CLDX Stock 12 Month Forecast

Average Price Target

$49.20

▲(84.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","68":"$68","28.25":"$28.3","41.5":"$41.5","54.75":"$54.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$67.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$49.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,28.25,41.5,54.75,68],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.29,28.498461538461537,31.706923076923076,34.91538461538462,38.12384615384615,41.332307692307694,44.54076923076923,47.74923076923077,50.95769230769231,54.16615384615385,57.37461538461539,60.58307692307692,63.791538461538465,{"y":67,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.29,27.12923076923077,28.96846153846154,30.807692307692307,32.64692307692307,34.48615384615385,36.325384615384614,38.16461538461539,40.003846153846155,41.84307692307692,43.682307692307695,45.52153846153846,47.360769230769236,{"y":49.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.29,25.267692307692307,25.245384615384616,25.223076923076924,25.20076923076923,25.178461538461537,25.156153846153845,25.133846153846154,25.111538461538462,25.08923076923077,25.066923076923075,25.044615384615383,25.02230769230769,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.4,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.23,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.49,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.29,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >